What antihypertensive regimen is recommended for a patient with a history of myocardial infarction?

Antihypertensive Management Post-MI

For patients with a history of myocardial infarction, beta-blockers and ACE inhibitors form the cornerstone of antihypertensive therapy and should be initiated in all patients unless contraindicated 1, 2.

First-Line Therapy

The evidence-based regimen prioritizes two drug classes with proven mortality benefit:

• Beta-blockers: Reduce cardiovascular mortality and should be continued indefinitely 1, 2, 3
• ACE inhibitors: Provide mortality reduction and prevent adverse ventricular remodeling; should be given indefinitely 1, 2, 3

For patients intolerant to ACE inhibitors, ARBs are the first-line alternative 1. This is explicitly stated in the AHA/ACC/ASH scientific statement, which notes ACE inhibitors are preferred over ARBs for those who can tolerate them.

Blood Pressure Targets

Target BP should be:

• <140/90 mm Hg for most post-MI patients 2, 3
• <130/80 mm Hg in patients with diabetes or chronic kidney disease 2, 3, 4
• <120/80 mm Hg for those with left ventricular dysfunction 4

Additional Agents When BP Goal Not Met

If beta-blockers and ACE inhibitors are insufficient to achieve BP targets, add:

1. Thiazide or thiazide-type diuretics as third-line therapy 1, 4
2. Dihydropyridine calcium channel blockers (e.g., amlodipine) can be added 4

Important caveat: Avoid non-dihydropyridine CCBs (verapamil, diltiazem) unless beta-blockers are contraindicated or not tolerated 4.

Special Populations

Post-MI with Heart Failure or LV Dysfunction (EF ≤40%)

Add aldosterone antagonists (eplerenone or spironolactone) to beta-blockers and ACE inhibitors 1. The EPHESUS trial demonstrated eplerenone reduced total mortality by 15% and cardiovascular mortality by 17% in post-MI patients with LV dysfunction, even when 87% were already on ACE inhibitors and 75% on beta-blockers 1.

Critical safety monitoring for aldosterone antagonists:

• Avoid if creatinine ≥2.5 mg/dL (men) or ≥2.0 mg/dL (women) 1
• Avoid if potassium ≥5.0 mEq/L 1
• Avoid if creatinine clearance <50 mL/min 1
• Requires close laboratory monitoring for hyperkalemia 1

Diuretic Selection in Heart Failure

For NYHA class III-IV heart failure or CKD with GFR <45 mL/min, use loop diuretics rather than thiazides 1. Exercise caution regarding hypokalemia, which may precipitate arrhythmias post-MI 1.

Common Pitfalls

• Underuse of aldosterone antagonists: These remain underutilized despite strong evidence, likely due to hyperkalemia concerns 1. When appropriate, they provide incremental mortality benefit beyond ACE inhibitors and beta-blockers.
• Premature discontinuation: Beta-blockers and ACE inhibitors should be continued indefinitely unless contraindications develop 2, 3
• Inadequate BP control: Most patients will require combination therapy with 2-3 agents to reach goal 5